Overview:
SetLance is a biotech company, founded in 2009, focusing its activity on the development of novel branched peptide-based drug candidates for the treatment of severe human diseases – with a special focus on bacterial infections and cancer, which are optimized, characterized in vitro, and developed in the preclinical, and early clinical phases. SetLance activity is currently based on the characterization and development of two proprietary lead peptides for bacterial infections and cancer. Antimicrobial peptide SET-M33 showed considerable activity against various multi-resistant Gram-negative bacteria and also against Staphylococcus aureus (D-stereoisomer).
SetLance-patented tetrabranched peptide containing human neurotensin sequence (NT4) efficiently discriminates between tumor and healthy tissue in human surgical samples of colon, pancreas adenocarcinoma and bladder cancer and is currently in the lead optimization phase and expected to enter preclinical-pharmacological stage in the next future.
